Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Xue-Song Sun¹,²,³,⁴†, Xiao-Hao Wang¹,²,³,⁴†, Sai-Lan Liu¹,²,³,⁴†, Dong-Hua Luo¹,²,³,⁴, Rui Sun¹,²,³,⁴, Li-Ting Liu¹,²,³,⁴, Shan-Shan Guo¹,²,³,⁴, Qiu-Yan Chen¹,²,³,⁴, Lin-Quan Tang¹,²,³,⁴* and Hai-Qiang Mai¹,²,³,⁴*

¹Sun Yat-sen University Cancer Center, Guangzhou, China, ²State Key Laboratory of Oncology in South China, Guangzhou, China, ³Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China, ⁴Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China

Objective: Our study aimed to compare the efficacy and toxicity of two chemotherapy regimens, gemcitabine plus cisplatin (GP) vs. docetaxel plus, fluorouracil plus cisplatin (TPF), in metastatic nasopharyngeal carcinoma (NPC) patients.

Methods: We retrospectively enrolled metastatic NPC patients between July 2006 and December 2016 who were treated with TPF or GP palliative chemotherapy (PCT). The association between the PCT regimens and survival conditions was evaluated by log-rank tests and the Cox proportional hazards model. A cohort was created using propensity score matching with the ratio of 1:1 to clarify the results of the multivariable Cox regression analyses. Overall survival (OS) was the primary endpoint.

Results: Of 266 eligible patients, 186 and 80 patients, respectively, received TPF and GP regimen. No significant difference was demonstrated in the survival rate between the GP and TPF groups (3-year OS: 52.6 vs. 50.3%; \( P = 0.929 \)). However, multivariable analysis suggested receiving GP as an independent protective factor (hazard ratio, 0.864; 95% confidence interval, 0.753–0.992; \( P = 0.042 \)). In the matched cohort, treatment with GP was also associated with a significantly higher OS (3-year OS: 52.6 vs. 35.6%, \( P = 0.042 \)). Subgroup analysis indicated that the superiority of GP reflected in patients with secondary metastases rather than primary metastases. The incidence of grade 3 to 4 treatment-related toxicity was more common in the TPF group than in the GP group.

Conclusion: Our study suggested that GP might be superior to TPF for metastatic NPC patients, especially those with secondary distant metastases. Further studies are necessary to validate our results.

Keywords: nasopharyngeal carcinoma, palliative chemotherapy, GP regimen, TPF regimen, survival
INTRODUCTION

Nasopharyngeal carcinoma (NPC) is a kind of malignancy arising from the nasopharyngeal mucosal lining. Different from other head and neck cancers, the incidence of NPC is obviously unbalanced across the world, with the highest incidence rate observed in South China (1). Because of its radiosensitivity, radiotherapy (RT) with or without chemotherapy is the standard treatment method for non-metastatic NPC (2, 3). Nowadays, distant metastases have become the main treatment failure and cause of death in NPC (4). Besides, approximately 15% of patients are detected to have distant metastases at the point of primary diagnosis (5). Once distant lesions are present, the prognosis is poor, and treatment mainly relies on systemic palliative chemotherapy (PCT) (6).

Various of platinum-based PCTs are widely applied in metastatic patients (7–9). However, it remains unknown which PCT regimen is the best, considering the trade-off between efficacy and toxicity. A randomized trial has verified that patients receiving gemcitabine plus cisplatin (GP) achieved better survival outcomes when compared with fluorouracil plus cisplatin (PF) (10). Meanwhile, in head and neck cancer, several large-scale phase III trials have shown the statistically significant survival benefits of adding docetaxel to the PF (TPF) induction regimen, and the superiority has also been observed in locally advanced NPC (11–15). Therefore, the comparison between the GP and TPF regimens is of great clinical significance. For non-metastatic NPC, Zhu et al. (16) demonstrated that the GP regimen was equivalent to TPF in treatment outcomes but with less toxicity. Up to now, no study has compared the efficacy and toxicity between TPF and GP in metastatic NPC.

In this study, we retrospectively enrolled 266 metastatic NPC patients receiving TPF or GP regimens. Based on the relatively large sample size, we compared the survival condition and acute toxicity of patients between these two PCT groups, in order to provide important information for determining the proper PCT regimen for metastatic NPC patients.

MATERIALS AND METHODS

Patient Selection and Pretreatment Evaluation

From July 2006 to December 2016, a total of 266 metastatic NPC patients treated in the Sun Yat Sen University Cancer Center were retrospectively enrolled into this study. The eligibility criteria were as follows: (1) biopsy-proven NPC; (2) evidence of distant metastasis confirmed by pathology or imaging examinations; (3) received GP or TPF regimen as the first-line treatment; (4) complete accessible treatment records; (5) aged ≥18 years; (6) adequate organ functions; (7) Karnofsky performance score >70; and (8) no pregnancy, lactation, or second malignancy. Our study was approved by the Research Ethics Committee of our center. The flowchart is described in Figure 1.

Pretreatment evaluations were performed in every enrolled patient, including physical examinations, fiberoptic nasopharyngoscopy, magnetic resonance imaging/computed tomography (CT) of the head and neck, and whole-body examination including chest X-rays/CT, abdominal sonography/abdominal CT, and bone scans. The positron emission tomography–CT was selectively performed based on clinician judgment. Complete blood count and biochemical profiles were also required.

Chemotherapy and Local Treatment

The GP and TPF regimens were administered as the first-line treatment in this study. The detailed regimens were as follows: TPF: docetaxel [60 mg/m$^2$ docetaxel intravenously (IV) given on day 1], cisplatin (20–25 mg/m$^2$ IV on days 1–3), and 5-fluorouracil (500–800 mg/m$^2$ continuous IV infusion for 24 h on days 1–5); GP: gemcitabine (800–1,000 mg/m$^2$ IV on days 1 and 8) and cisplatin (20–30 mg/m$^2$ IV on days 1–3). The cumulative dose of cisplatin was 60 to 75 mg/m$^2$ and 70 to 85 mg/m$^2$ in TPF and GP regimens, respectively. Based on the treatment principle in our center, patients with metastatic NPC were given four to six cycles of PCT. The treatment would be terminated or changed under the following conditions: disease progression, death, occurrence of intolerable toxicities, or at patient’s request. For patients with limited or localized metastatic lesions, local treatment, such as surgery, RT, or interventional ablative therapy, was considered according to the clinician’s judgment.

Outcome and Follow-Up

Overall survival (OS) was the primary endpoint, calculated from the date of diagnosis to death. Patients who were lost to follow-up or alive had their follow-ups censored at the last visit. Patients were routinely followed up every 3 months during the first year and every 6 months thereafter until death. Magnetic resonance imaging or CT of the head and neck, chest X-rays/CT, abdominal sonography/CT, and bone scans were generally performed.

STATISTICAL ANALYSES

The patients’ baseline characteristics between the two groups were evaluated by the $\chi^2$-test. Kaplan–Meier survival curves were used to estimate the OS curves, and the difference was compared by log-rank test. A multivariable Cox regression model was utilized to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs). The propensity score matching (PSM) method was applied to balance potential confounders, using a 1:1 matching protocol with a greedy-matching algorithm, and the caliper width equaled 0.05. The following factors were included in the matching process: age, gender, smoking history, primary or secondary metastases, number of metastatic organs, chemotherapy cycles, and local treatment. To evaluate the predictive accuracy of Epstein-Barr virus (EBV) DNA, the time-dependent (3-year) receiver operating characteristic (ROC) analysis was applied. The area under the ROC curve (AUC) was calculated to assess the sensitivity and specificity of EBV DNA to predict death. The cutoff value of EBV DNA was selected based on the minimum P (highest $\chi^2$) value defined by log-rank test (17). Kaplan–Meier survival curve and Cox regression model were used to explore the prognostic value of EBV DNA. Interaction analysis based on the Cox proportional hazards model was performed between chemotherapy regimens.
and the state of metastasis, primary or secondary. The efficacy of two regimens was compared in the subgroups of either primary or secondary disease. All analyses were two-sided, and a two-tailed $P < 0.05$ indicated a difference with statistical significance. The statistical analyses were performed using SPSS for Mac version 23.0 (SPSS Inc., Chicago, IL, USA), R 3.5.1 (R Project, Vienna, Austria) and X-tile software (V.3.6.1; Yale University, New Haven, CT, USA).

**RESULTS**

**Patient Characteristics**

Of the entire cohort, the median age was 47 years with a male-to-female ratio of 4.5:1. There were 186 patients and 80 patients, respectively, assigned to the TPF and GP groups. As shown in Table 1, there was a significantly higher proportion of patients with multiple metastatic organs (40.0 vs. 25.8%, $P = 0.028$) and secondary metastasis in the GP group (62.5 vs. 27.4%, $P < 0.001$). The median accumulative cisplatin dose was 320 mg/m$^2$. Patients in the GP group received higher intensity of cisplatin treatment ($P < 0.001$). Other baseline characteristics were in good balance between the two treatment groups.

**Survival Analysis**

The cutoff of data for OS analysis was on July 1, 2019. With a median follow-up of 26.7 months (range, 1.2–137.9 months), 143 patients (53.8%) died during follow-up, including 104/186 (55.9%) in the TPF group and 39/80 (48.6%) in the GP group. The 1-, 3-, and 5-year survival rates for the entire cohort were 87.9, 51.6, and 36.6%, respectively. The OS rates were similar between patients who received GP and TPF (3-year OS: 52.6 vs. 50.3%; $P = 0.929$) (Figure 2A). However, after adjusting for other variables, GP was shown to be an independent protective factor (GP vs. TPF: HR, 0.864; 95% CI, 0.753–0.992; $P = 0.042$) in multivariable analysis (Table 2). Besides, patients with secondary metastases (HR, 1.567; 95% CI, 1.064–2.308; $P = 0.023$) and multiple metastatic organs (HR, 2.137; 95% CI, 1.459–3.129; $P < 0.001$) were also associated with worse survival outcomes. To further clarify the results of the multivariable analyses, a cohort of 160 patients were created using the PSM. All of the patients in GP group find a close unique match in TPF.
application of GP regimen contributed to survival prolongation, patients' survival in the matched cohort and found that the two treatment groups were well-balanced. We then compared P with a significantly higher OS rate (3-year OS: 52.6 vs. 35.6%, \( P = 0.042 \)). The optimal cutoff value of EBV DNA was found to be an independent risk factor for OS (3-year OS: 70.2 vs. 46.2%, \( P = 0.001 \)). An additional multivariable model was made in these patients, and the EBV DNA level was found to be an independent risk factor for OS (30,000 copies/mL: HR, 1.381–3.373; \( P = 0.001 \)).

### TABLE 1 | Clinical characteristics in whole cohort.

| Characteristics                  | TPF (n = 186) | GP (n = 80) | \( P \) |
|----------------------------------|---------------|-------------|--------|
| **Age (years)**                  |               |             |        |
| \( \leq 47 \)                    | 93 (50.0%)    | 42 (52.5%)  | 0.789  |
| \( > 47 \)                       | 93 (50.0%)    | 38 (47.5%)  |        |
| **Gender**                       |               |             |        |
| Male                             | 154 (82.8%)   | 64 (80.0%)  | 0.604  |
| Female                           | 32 (17.2%)    | 16 (20.0%)  |        |
| **Smoking history**              |               |             |        |
| Non-smokers                      | 99 (53.2%)    | 48 (60.0%)  | 0.348  |
| Smokers                          | 87 (46.8%)    | 32 (40.0%)  |        |
| **Time order**                   |               |             |        |
| Primary metastases               | 135 (72.6%)   | 30 (37.5%)  | <0.001 |
| Secondary metastases             | 51 (27.4%)    | 50 (62.5%)  |        |
| **No. of metastatic organs**     |               |             |        |
| Oligo                            | 138 (74.2%)   | 48 (60.0%)  | 0.028  |
| Multiple                         | 48 (25.8%)    | 32 (40.0%)  |        |
| **Chemotherapy cycles**          |               |             |        |
| \( \leq 4 \)                     | 85 (45.7%)    | 33 (41.3%)  | 0.591  |
| \( > 4 \)                        | 101 (54.3%)   | 47 (58.8%)  |        |
| **Total platinum dose (mg/m\(^2\))** |           |             |        |
| Median (range)                   | 300 (60–600)  | 420 (80–800)| <0.001 |
| **Local treatment of metastases**|               |             |        |
| No                               | 157 (84.4%)   | 73 (91.3%)  | 0.172  |
| Yes                              | 29 (15.6%)    | 7 (8.8%)    |        |
| **EBV DNA**                      |               |             |        |
| \( \leq 30,000 \) copies/mL      | 69 (43.9%)    | 19 (42.2%)  | 0.866  |
| \( > 30,000 \) copies/mL         | 88 (56.1%)    | 26 (57.8%)  |        |

TPF, cisplatin plus docetaxel plus 5-fluorouracil; GP, cisplatin plus gemcitabine; EBV, Epstein–Barr virus.

The \( P \)-value was calculated using the Pearson \( \chi^2 \)-test and t-test (*). Two hundred two patients had the data of EBV DNA.

As shown in Table S1, the characteristics between the two treatment groups were well-balanced. We then compared patients' survival in the matched cohort and found that the application of GP regimen contributed to survival prolongation, with a significantly higher OS rate (3-year OS: 52.6 vs. 35.6%, \( P = 0.042 \)).

Two hundred two patients had EBV DNA levels measured at admission. We analyzed the effect of EBV DNA on prognosis among these patients. EBV DNA had a satisfactory value in the prediction of death concerning time-dependent 3-year ROC (AUC = 0.675). The optimal cutoff value of EBV DNA was 30,300 copies/mL, which was generated by X-tile plots. For better clinical application, the cutoff value was rounded to 30,000 copies/mL. As shown in Figure 3B, lower EBV DNA level (\( \leq 30,000 \) copies/mL) was significantly associated with better survival condition (3-year OS: 70.2 vs. 46.2%, \( P < 0.001 \)).

Subgroup Analysis

As the multivariable analysis demonstrated, whether metastases occurred primarily or secondarily was an independent prognostic factor. The 3-year OS rates were 56.9 and 41.1%, respectively, for primary and secondary disease (\( P = 0.003 \)). Therefore, a subgroup analysis was conducted to explore the impact of different PCT regimens based on the state of metastasis. The clinical characteristics of patients with primary/secondary metastases were shown in Table 3. Interestingly, the superiority of GP in OS was observed only in patients with secondary metastases (3-year OS: 51.9 vs. 29.0%, \( P = 0.035 \)), whereas no significant difference was found in primary metastatic NPC patients (3-year OS: 53.4 vs. 57.6%, \( P = 0.601 \)).

Toxicity

The differences of grade 3 to 4 adverse events (AEs) between 2 PCT regimens were analyzed in our study (Table 5). The two most common grade 3 to 4 AEs were leukopenia and neutropenia. Besides, a higher frequency of G3 to G4 neutropenia was observed in the TPF group (41.9 vs. 25.0%, \( P = 0.012 \)).

DISCUSSION

To our knowledge, this is the first study to compare the efficacy and safety of TPF to GP in metastatic NPC. Compared with TPF, the administration of GP was a protective factor for OS with fewer G3–G4 AEs. According to the results, GP could serve as first-line treatment for metastatic NPC patients, in particular for those with secondary metastases. Prospective and large-sample studies are needed to validate our results.

Nowadays, with the development of RT technology, NPC patients have obtained satisfactory local regional control. Distant metastasis remains a major challenge in the management of NPC and also the leading cause of death (4, 18). Because of the huge tumor burden for metastatic patients, platinum-based systemic palliative therapy has become the main treatment method with objective response rates of 55 to 80% (7–9). However, the duration of response is short, and the long-term survival is still poor (19). Which PCT regimen is the best choice is still under discussion.
For locally advanced NPC, patients receiving TPF achieved better survival when compared with PF and (docetaxel plus cisplatin) TP, which was considered as the most effective chemotherapy regimen (14, 15). Unfortunately, the triple regimen also brought a higher incidence of treatment-related AEs (15). Because multiple cycles of chemotherapy were indispensable, the tolerability of chemotherapy regimens became a big issue faced by metastatic patients. Therefore, an effective and tolerable PCT regimen for these patients was in urgent need.

Gemcitabine is a ribonucleotide reductase inhibitor, which shows a broad-spectrum antitumor activity, including NPC (20). More importantly, gemcitabine can enhance the activity of cisplatin by increasing the formation of DNA adducts induced by platinum and inhibiting the activity of ERCC1, which is an important mechanism of platinum resistance (21). The synergistic effect of cisplatin and gemcitabine has been verified in a variety of human tumor cells in vitro (22, 23). At present, this combination is used in the treatment for a variety of malignant tumors (24, 25). Among locally advanced NPC patients, a multicenter phase III trial demonstrated that GP induction chemotherapy (IC) significantly improved the survival condition when compared with concurrent chemoradiotherapy alone (26). Compared with a PF regimen, cost-effectiveness analysis proved that GP was more cost-effective than the traditional regimen (27). Moreover, in patients with recurrent or metastatic NPC, Zhang et al. (10) verified the superiority of GP over PF in terms of

![FIGURE 2](image-url) Kaplan–Meier OS curves for the metastatic patients receiving GP and TPF (A) in the whole cohort; (B) in the PSM cohort. OS, overall survival; GP, gemcitabine plus cisplatin; TPF, docetaxel plus fluorouracil plus cisplatin; PSM, propensity score matching.

### TABLE 2 | Multivariable analysis.

| Characteristic                                | Model 1          |                          | Model 2#                |                          | Model 3          |                          |
|-----------------------------------------------|------------------|--------------------------|-------------------------|--------------------------|------------------|--------------------------|
|                                               | HR   | 95% CI | P     | HR   | 95% CI | P     | HR   | 95% CI | P     |
| Age (years)                                   | 1.320 | 0.931–1.870 | 0.119 | 1.390 | 0.897–2.155 | 0.140 | 1.307 | 0.927–1.844 | 0.126 |
| Gender                                        | 1.197 | 0.791–1.810 | 0.394 | 0.942 | 0.533–1.663 | 0.836 | 1.139 | 0.754–1.721 | 0.537 |
| Smoking history                               | 1.052 | 0.749–1.477 | 0.769 | 1.282 | 0.837–1.963 | 0.254 | 1.127 | 0.798–1.591 | 0.498 |
| Time order                                    | 1.567 | 1.064–2.308 | 0.023 | 1.603 | 1.109–2.548 | 0.027 | 2.801 | 1.557–5.040 | 0.001 |
| No. of metastatic organs                      | 2.137 | 1.459–3.129 | <0.001 | 2.997 | 1.856–4.838 | <0.001 | 2.259 | 1.540–3.315 | <0.001 |
| Chemotherapy cycles                           | 1.063 | 0.665–1.700 | 0.798 | 1.050 | 0.671–1.642 | 0.832 | 1.052 | 0.734–1.507 | 0.783 |
| Local treatment of metastases                 | 0.656 | 0.379–1.138 | 0.134 | 0.902 | 0.477–1.709 | 0.753 | 0.628 | 0.364–1.082 | 0.094 |
| Total platinum dose                           | 1.007 | 0.599–1.696 | 0.978 | 0.666 | 0.340–1.305 | 0.237 | 1.024 | 0.610–1.719 | 0.928 |
| Chemotherapy regimens                         | 0.864 | 0.753–0.992 | 0.042 | 0.752 | 0.700–0.978 | 0.022 | 0.932 | 0.747–1.157 | 0.552 |
| EBV DNA level                                  | 2.159 | 1.381–3.373 | 0.001 | 0.740 | 0.568–0.966 | 0.026 |

HR, hazard ratio; CI, confidence interval; TPF, cisplatin plus docetaxel plus 5-fluorouracil; GP, cisplatin plus gemcitabine; EBV, Epstein–Barr virus.

A Cox proportional hazards model was used to perform multivariable analyses. All variables were transformed into categorical variables. HRs were calculated for age (years) (>47 vs. ≤47); gender (male vs. female); smoking history (smokers vs. non-smokers); time order (secondary metastases vs. primary metastases); number of metastatic organs (multiple vs. oligo); chemotherapy cycles (>4 vs. ≤4); local treatment of metastases (yes vs. no); total platinum dose (≥320 vs. <320 mg/m²); and chemotherapy regimens (GP vs. TPF); EBV DNA (>30,000 copies/mL vs. ≤30,000 copies/mL).

# Two hundred two patients who had the data of EBV DNA were involved in Model 2.
efficacy and toxicity. However, no study directly compared the efficacy of GP to TPF, and the latter one has been considered a stronger PCT regimen when compared to PF in metastatic NPC patients.

In the present study, we compared these two PCT regimens in 266 metastatic patients and found that the OS was similar between the two groups (50.3 vs. 52.6%; \( P = 0.929 \)). However, it should be noted that the patient's characteristics were unbalanced between the two groups, and we observed higher proportions of multiple metastatic organs (\( P = 0.028 \)) and secondary metastases in the GP group (\( P < 0.001 \)). After adjusting for important variables, GP was an independent protective factor with a 14.0% lower risk of death as compared to the TPF group in multivariable analysis. In the matched cohort, a higher 3-year OS in the GP group was also achieved (52.6 vs. 35.6%, \( P = 0.042 \)). Comparison between the two regimens indicated that the triple regimen resulted in a higher grade 3–4 AEs in neutropenia (\( P = 0.012 \)) and mucositis (\( P < 0.001 \)). The incidences of grade 3–4 AEs in the GP group were similar to a previous clinical trial (10).
TABLE 3 | Clinical characteristics of patients in primary/secondary metastases subgroups.

| Characteristic          | Primary metastases n = 165 | Secondary metastases n = 101 |
|-------------------------|----------------------------|------------------------------|
|                         | TPF (n = 135) | GP (n = 30) | P    | TPF (n = 51) | GP (n = 50) | P    |
| Age (years)             |               |               |      |               |               |      |
| ≤47                     | 63 (46.7%)    | 12 (40.0%)    | 0.549| 30 (58.8%)    | 30 (60.0%)    | 1.000|
| >47                     | 72 (53.3%)    | 18 (60.0%)    |      | 21 (41.2%)    | 20 (40.0%)    |      |
| Gender                  |               |               |      |               |               |      |
| Male                    | 113 (83.7%)   | 24 (80.0%)    | 0.788| 28 (54.9%)    | 27 (54.0%)    | 1.000|
| Female                  | 22 (16.3%)    | 6 (20.0%)     |      | 23 (45.1%)    | 23 (46.0%)    |      |
| Smoking history         |               |               |      |               |               |      |
| Non-smokers             | 71 (52.6%)    | 21 (70.0%)    | 0.104| 28 (54.9%)    | 27 (54.0%)    | 1.000|
| Smokers                 | 64 (47.4%)    | 9 (30.0%)     |      | 23 (45.1%)    | 23 (46.0%)    |      |
| No. of metastatic organs|               |               |      |               |               |      |
| Oligo                   | 106 (78.5%)   | 22 (73.3%)    | 0.629| 32 (62.7%)    | 26 (52.0%)    | 0.318|
| Multiple                | 29 (21.5%)    | 8 (26.7%)     |      | 19 (37.3%)    | 24 (48.0%)    |      |
| Chemotherapy cycles     |               |               |      |               |               |      |
| ≤4                      | 113 (83.7%)   | 29 (96.7%)    | 0.080| 44 (86.3%)    | 44 (88.0%)    | 1.000|
| >4                      | 22 (16.3%)    | 1 (3.3%)      |      | 7 (13.7%)     | 6 (12.0%)     |      |
| Local treatment of metastases |         |               |      |               |               |      |
| No                      | 61 (45.2%)    | 13 (43.3%)    | 1.000| 24 (47.1%)    | 20 (40.0%)    | 0.549|
| Yes                     | 74 (54.8%)    | 17 (56.7%)    |      | 27 (52.9%)    | 30 (60.0%)    |      |

TPF, cisplatin plus docetaxel plus 5-fluorouracil; GP, cisplatin plus gemcitabine.
The P-value was calculated using the Pearson χ²-test.

Additionally, our group verified that secondary metastases were associated with worse prognosis than primary metastases. Interaction analysis showed that interaction effect existed between chemotherapy regimens and the state of metastases occurrence. Therefore, we performed subgroup analysis in patients with different state of metastases. Interestingly, the superiority of GP over TPF was consistently seen only in patients with secondary metastases. This result could be partially explained by the following. On the one hand, the oral health status of NPC patients after RT is generally poor, and it can be further aggravated by receiving fluorouracil and cisplatin regimen because it may lead to severe mucositis. As the adverse reactions are intolerable, the patients are more likely to discontinue the treatment (10). In addition, deep vein catheterization for fluorouracil infusion also increases the risk of catheter-related infection and thromboembolism, which also compromised their survival rates (28). These conditions affect the efficacy of TPF regimen. However, as for GP regimen, the most common blood toxicity can be more easily identified and dealt with. On the other hand, fluorouracil or taxol-containing
TABLE 4 | Multivariable analyses in primary metastatic and secondary metastatic patients.

| Characteristic                  | Primary metastases | Secondary metastases |
|---------------------------------|--------------------|----------------------|
|                                 | HR 95% CI          | P                    |
|                                 |                    |                      |
| Age (years)                     | 1.259 0.788–2.012  | 0.335                |
|                                 | 1.398 0.832–2.349  | 0.206                |
| Gender                          | 0.987 0.539–1.809  | 0.967                |
|                                 | 1.375 0.760–2.486  | 0.292                |
| Smoking history                 | 1.298 0.813–2.071  | 0.275                |
|                                 | 0.923 0.546–1.561  | 0.764                |
| No. of metastatic organs        | 2.780 1.638–4.718  | <0.001               |
|                                 | 1.845 1.051–3.239  | 0.033                |
| Chemotherapy cycles             | 1.265 0.644–2.484  | 0.496                |
|                                 | 0.768 0.396–1.491  | 0.435                |
| Local treatment of metastases   | 0.838 0.406–1.730  | 0.632                |
|                                 | 0.432 0.183–1.017  | 0.055                |
| Total platinum dose             | 0.993 0.485–2.034  | 0.984                |
|                                 | 0.964 0.457–2.117  | 0.967                |
| Chemotherapy regimens           | 1.069 0.855–1.337  | 0.557                |
|                                 | 0.797 0.614–0.982  | 0.022                |

HR, hazard ratio; CI, confidence interval; TPF, cisplatin plus docetaxel plus 5-fluorouracil; GP, cisplatin plus gemcitabine.
Data were obtained from all 266 patients included in the study.
A Cox proportional hazards model was used to perform multivariable analyses. All variables were transformed into categorical variables. HRs were calculated for age (years) (>47 vs. ≤47); gender (male vs. female); smoking history (smokers vs. non-smokers); number of metastatic organs (multiple vs. oligo); chemotherapy cycles (>4 vs. ≤4); local treatment of metastases (yes vs. no); total platinum dose (≥320 vs. <320 mg/m²); and chemotherapy regimens (GP vs. TPF).

TABLE 5 | Acute toxicities during chemotherapy between the two groups.

|                 | TPF (n = 186) | GP (n = 80) | P     |
|-----------------|---------------|-------------|-------|
|                 | No. (%)       | No. (%)     |       |
| Leukocytopenia  |               |             |       |
| G0–2            | 122 (65.6%)   | 57 (71.3%)  | 0.395 |
| G3–4            | 64 (34.4%)    | 23 (28.8%)  |       |
| Neutropenia     |               |             |       |
| G0–2            | 108 (58.1%)   | 60 (75.0%)  | 0.012 |
| G3–4            | 78 (41.9%)    | 20 (25.0%)  |       |
| Anemia          |               |             |       |
| G0–2            | 168 (90.3%)   | 76 (95.0%)  | 0.235 |
| G3–4            | 18 (9.7%)     | 4 (5.0%)    |       |
| Thrombocytopenia|               |             |       |
| G0–2            | 171 (91.9%)   | 68 (85.0%)  | 0.119 |
| G3–4            | 15 (8.1%)     | 12 (15.0%)  |       |
| Hepatotoxicity  |               |             |       |
| G0–2            | 179 (96.2%)   | 78 (97.5%)  | 0.728*|
| G3–4            | 7 (3.8%)      | 2 (2.5%)    |       |
| Nephrotoxicity  |               |             |       |
| G0–2            | 185 (99.5%)   | 80 (100.0%) | 1.000*|
| G3–4            | 1 (0.5%)      | 0 (0.0%)    |       |
| Mucositis       |               |             |       |
| G0–2            | 164 (88.2%)   | 80 (10.0%)  | <0.001|
| G3–4            | 22 (11.8%)    | 0 (0.0%)    |       |

The P-value was calculated using the Pearson χ²-test or Fisher exact test (*).

regimens are widely used as the IC for locally advanced NPC. For patients who developed metastases after primary treatment, the previous use of fluorouracil or taxol-containing IC might have led to chemotherapy resistance of the corresponding drugs and will weaken the efficacy of the subsequent palliative TPF regimen to some degrees (29, 30). Unfortunately, as some patients did not receive the initial treatment in our center, the previous treatment details were inaccessible; thus, we could not provide the relevant information in current study.

Our study showed the advantage of GP in improving efficacy and reducing toxicities when compared with TPF in metastatic NPC, and we recommended the use of GP as first-line treatment, especially for metastases after primary treatment. Besides, the administration of GP regimen is also simpler than TPF, and outpatient treatment is feasible, which could reduce costs for patients and the stress of hospital stay.

There were several limitations to the current study. First, this was a retrospective study, and the selective bias was unavoidable. Therefore, we performed multivariable analysis to eliminate confounding factors to some extent, and the well-balanced cohort using the PSM was considered to eliminate potential confounders between patients who received TPF and GP. Besides, it is difficult to determine the accurate disease progression time because of the retrospective design. Therefore, OS was the only endpoint in current study. Second, in view of the different types of failure pattern, cause of death, and prognosis between recurrent and metastatic NPC, patients with local recurrence were not included in this study. Third, some patients only used chest X-ray and abdominal ultrasound to evaluate their metastatic conditions, which offered limited evaluative value to treatment response. Finally, all patients involved in this study were from an endemic area, and the predominant histology is the undifferentiated non-keratinizing carcinoma. Whether the results could be applied to non-endemic areas needs to be verified. A well-designed prospective clinical trial is necessary to validate our results.

CONCLUSION

Our study suggests that the GP PCT regimen achieved better efficacy compared to the TPF PCT regimen among patients with secondary metastatic NPC. The incidence of grade 3–4 AEs was relatively lower in the GP group than in the TPF group. Prospective studies are awaited to validate our results.
DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

This retrospective study was approved by the Clinical Research Committee of Sun Yat Sen University Cancer Center. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

H-QM, L-QT, and Q-YC: study concepts. X-SS, X-HW, and S-LL: study design. X-SS, X-HW, S-LL, D-HL, RS, L-TL, and S-SG: data acquisition. X-SS, X-HW, and S-LL: quality control of data and algorithms. X-SS, X-HW, RS, D-HL, L-TL, S-SG, and L-TL: data analysis and interpretation. X-SS, X-HW, and S-LL: statistical analysis. X-SS, X-HW, S-LL, RS, D-HL, L-TL, S-SG, H-QM, L-QT, and Q-YC: article preparation. X-SS, X-HW, and S-LL: article editing. X-SS, X-HW, S-LL, RS, D-HL, L-TL, S-SG, L-QT, Q-YC, and H-QM: article review. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from the National Key R&D Program of China (2017YFC1309003, 2017YFC0908500), the National Natural Science Foundation of China (Nos. 81425018, 81672868, and 81802775), the Sci-Tech Project Foundation of Guangzhou City (201707020039), the Sun Yat-sen University Clinical Research 5010 Program, the Special Support Plan of Guangdong Province (No. 2014TX01R145), the Natural Science Foundation of Guangdong Province (Nos. 2017A030312003 and 2018A0303131004), the Natural Science Foundation of Guangdong Province for Distinguished Young Scholar (No. 2018B030306001), the Sci-Tech Project Foundation of Guangdong Province (No. 2014A020212103), the Health & Medical Collaborative Innovation Project of Guangzhou City (Nos. 201400000001 and 201803040003), Pearl River S&T Nova Program of Guangzhou (No. 201806010135), the Planned Science and Technology Project of Guangdong Province (2019B020230002), the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (No. 2014BA109B10), and the Fundamental Research Funds for the Central Universities.

ACKNOWLEDGMENTS

We kindly thank the editor and reviewers for their careful review and valuable comments, which have led to a significant improvement of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.01295/full#supplementary-material

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492
2. Chan A, Teo P, Ngan R, Leung T, Lau W, Zee B, et al. Concurrent chemoradiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. (2002) 20:2038–44. doi: 10.1200/JCO.2002.08.149
3. Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. (2013) 11:917–23. doi: 10.6004/jnccn.2013.0113
4. Sun XS, Liu SL, Luo MX, Li XY, Chen QY, Guo SS, et al. The association between the development of radiation therapy, image technology, and chemoradiotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to (2012). Int J Radiat Oncol Biol Phys. (2019) 105:581–90. doi: 10.1016/j.ijrobp.2019.06.2549
5. Tang L, Chen Q, Fan W, Liu H, Zhang L, Guo L, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. (2013) 31:2861–9. doi: 10.1200/JCO.2012.46.0816
6. Wei WL, Sham JS. Nasopharyngeal carcinoma. Lancet (London, England). (2003) 365:2041–54. doi: 10.1016/S0140-6736(05)66698-6
7. Ji J, Yun T, Kim S, Kang J, Park J, Cho I, et al. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01). Eur J Cancer. (2012) 48:3196–204. doi: 10.1016/j.ejca.2012.06.009
8. Ngan R, Yiu H, Lau W, Yau S, Cheung F, Chan T, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. (2002) 13:1252–8. doi: 10.1093/annonc/mdf200
9. Chen C, Wang F, An X, Luo H, Wang Z, Liang Y, et al. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. Cancer Chemother Pharmacol. (2013) 71:371–8. doi: 10.1007/s00280-012-2020-x
10. Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet (London, England). (2016) 388:1883–92. doi: 10.1016/S0140-6736(16)31388-5
11. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. (2007) 357:1695–704. doi: 10.1056/NEJMoa070128
12. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. (2007) 357:1705–15. doi: 10.1056/NEJMoa070956
13. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. (2009) 101:498–506. doi: 10.1093/jnci/dip007
14. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. *Lancet Oncol.* (2011) 12:153–9. doi: 10.1016/S1470-2045(10)70279-5

15. Peng H, Tang LL, Chen BB, Chen L, Li WF, Mao YP, et al. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma: a big-data intelligence platform-based analysis. *Oral Oncol.* (2018) 79:40–6. doi: 10.1016/j.oraloncology.2018.02.011

16. Zhu J, Duan B, Shi H, Li Y, Ai P, Tian J, et al. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma. *Oral Oncol.* (2019) 97:37–43. doi: 10.1016/j.oraloncology.2019.08.001

17. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res.* (2004) 10:7252–9. doi: 10.1158/1078-0432.CCR-04-0713

18. Zhang M, Li J, Shen G, Zou X, Xu J, Jiang R, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. *Eur J Cancer.* (2015) 51:2587–95. doi: 10.1016/j.ejca.2015.08.006

19. Jin Y, Shi XY, Cai XY, Xia XY, Cai YC, Cao Y, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. *J Cancer Res Clin Oncol.* (2012) 138:1717–25. doi: 10.1007/s00432-012-1219-x

20. Chua ML, Chan AT. Gemcitabine: a game changer in nasopharyngeal carcinoma. *Lancet (London, England).* (2016) 388:1853–4. doi: 10.1016/S0140-6736(16)31394-0

21. Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. *Int J Oncol.* (2006) 28:237–44. doi: 10.3892/ijo.28.1.237

22. Peters GJ, Van Moorsel CJ, Bakker C, Bindslev K, Noordhuis P, Comijn EC, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. *Int J Oncol.* (2006) 28:237–44. doi: 10.3892/ijo.28.1.237

23. Brewer CA, Blessing IA, Nagourney RA, Morgan M, Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the gynecologic oncology group. *Gynecol Oncol.* (2006) 103:446–50. doi: 10.1016/j.ygyno.2006.03.018

24. Nagourney RA, Brewer CA, Radecki S, Kidder WA, Sommers BL, Evans SS, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. *Gynecol Oncol.* (2003) 88:35–9. doi: 10.1006/gyno.2002.6855

25. Chun SH, Lee JE, Park MH, Kang JH, Kim YK, Wang YP, et al. Gemcitabine plus platinum combination chemotherapy for elderly patients with advanced non-small cell lung cancer: a retrospective analysis. *Cancer Res Treat.* (2011) 43:217–24. doi: 10.4143/ct.2011.43.4.217

26. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. *N Engl J Med.* (2019) 381:1124–35. doi: 10.1186/40880-019-0385-5

27. Chen X, Liang W, Wang N, Zhang L, Yang J, Jiang J, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. *Oral Oncol.* (2019) 94:80–5. doi: 10.1016/j.oraloncology.2019.04.022

28. Liang YJ, Tang LQ, Sun XS, Fan YY, Yan JJ, Du YY, et al. Symptomatic venous thromboembolism associated with peripherally inserted central catheters predicts a worse survival in nasopharyngeal carcinoma: results of a large cohort, propensity score-matched analysis. *BMC Cancer.* (2018) 18:1297. doi: 10.1186/s12885-018-5213-9

29. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. *J Pathol.* (2005) 203:275–92. doi: 10.1002/path.1706

30. Zhao J. Cancer stem cells and chemoresistance: the smartest survives the raid. *Pharmacol Ther.* (2016) 160:145–58. doi: 10.1016/j.pharmthera.2016.02.008

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.